Atypical fibroxanthoma: An analysis of 105 tumors
| Autor: | Alena Bitel, Claudia Krönert, Uwe Wollina, Jacqueline Schönlebe |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Skin Neoplasms Dermatology Metastasis Malignant transformation Diagnosis Differential 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Medicine Humans Aged High rate Aged 80 and over Tumor size business.industry Atypical fibroxanthoma Sarcoma General Medicine medicine.disease 030220 oncology & carcinogenesis Histopathology Female Radiology Skin cancer Neoplasm Recurrence Local business |
| Zdroj: | Dermatologic therapyREFERENCES. 33(6) |
| ISSN: | 1529-8019 |
| Popis: | Atypical fibroxanthoma (AFX) is a rare, low-grade dermal sarcoma. We analyzed our files from January 2001 to January 2020 for AFX. Clinical parameters, histopathology, treatment and outcome have been investigated. We identified 87 patients (mean age of 80.0 ± 8.4 years) with 105 confirmed tumors. Of these patients 86.2% were males. The most common clinical presentation was nodular (93.3%). The majority of AFX was located on the head with a mean tumor diameter of 15.0 mm ± 3.5 mm. All tumors showed a dermal localization, in 46.4% with a focal infiltration of the deeper layers. Second skin cancer was reported in 62.1% of patients. Collision tumors were seen in six patients. Treatment was surgical with three-dimensional margin control. Relapses were noted in 11.4% of tumors with a mean delay of 11.7 ± 17.3 months. Focally deeper infiltration of AFX was a risk factor (P = .014). None of the purely dermal AFX relapsed. No metastasis was observed. AFX is a rare mesenchymal tumor of elderly patients. Treatment of choice is the complete surgical excision. Due to the high rate of other skin malignancies among patients with AFX, a regular follow-up is recommended. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|